TGFβ can reduce the sensitivity of HCC cells to sorafenib or doxorubicin, and the exosomal lncRNA ROR helps recipient cells acquire chemoresistance in HCC by activating the TGFβ signal pathway (Fig. 3). Here, LINC-ROR is linked to hepatocellular carcinoma.